Taken together, the Aβ oligomerization profiles in nasal discharge may vary depending on the AD progression, shown by the higher expression of Aβ*56 in the mild stage and higher expressions of both Aβ*56 and AβO in the moderate stage compared to the normal group. This evidence concerns the gene ABO and Alzheimer disease.